(Q43128788)

English

A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.

scientific article published on 15 March 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20231298%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20231298%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Vladimir Moiseyenko

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20231298%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

P Zatloukal

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20231298%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

F Cardenal

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20231298%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

A Szczesna

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20231298%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

V Gorbunova

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20231298%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

X Zhang

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20231298%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

L Cisar

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20231298%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

J-C Soria

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20231298%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

M Domine

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20231298%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

M Thomas

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20231298%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

15 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20231298%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20231298%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20231298%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20231298%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1810-1816

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20231298%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Progress in treatment of small-cell lung cancer: role of CPT-11.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ036

21 January 2018

Irinotecan (CPT-11): pharmacology and clinical applications

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ036

21 January 2018

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ036

21 January 2018

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ036

21 January 2018

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ036

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ036

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ036

21 January 2018

Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ036

21 January 2018

A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ036

21 January 2018

Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ036

21 January 2018

Interpreting disparate responses to cancer therapy: the role of human population genetics

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ036

21 January 2018

Targeted disruption of the HFE gene

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ036

21 January 2018

Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ036

21 January 2018

Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ036

21 January 2018

Identifiers

10.1093/ANNONC/MDQ036

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20231298%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20231298%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43128788&oldid=1598089118"